Abstract
Rapid drug regulatory decisions regarding phenylpropanolamine (PPA)-containing common cold remedies and diet pills were taken in some Latin American countries following a Food and Drug Administration (FDA) decision in the US. This situation is described as one that illustrates the important changes that regulatory decisions are experiencing as a consequence of globalisation.
The evidence for the efficacy of PPA as a nasal decongestant and as an appetite-suppressant is very limited, at least by modern standards. Its potential to increase blood pressure and induce haemorrhagic stroke was described soon after its marketing. Although this poor benefit/risk ratio had been known for more than 20 years, regulatory action was taken in Latin America only after the US FDA withdrew the drug in the US on the basis of the results of a case-control study which added limited new evidence to the already known risk of stroke, but which, on the other hand, had attracted much attention from the media.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Stolley PD, Laporte JR. The public health, the university, and pharmacoepidemiology. In: Strom BL, editor. Pharmacoepidemiology. New York; John Wiley & Sons Ltd, 2000
Glaxo withdraws grepafloxacin worldwide. Scrip 1999; 2485: 21
Tolcapone and fatal liver injury.WHO Drug Information 1999; 13: 17
Rawlins, MD. Adverse reactions to drugs. BMJ 1981; 282: 974–6
‘E-drug’ discussion list [online]. Available from URL: http://www.healthnet.org/programs/edrug.html [Accessed 2002 Jul 16]
‘E-farmacos’ discussion list [online]. Available from URL: http://www.healthnet.org/programs/efarmacos.html [Accessed 2002 Jul 16]
Johnson DA, Etter HS, Reeves DH. Stroke and phenylpropanolamine use [letter]. Lancet 1983; II: 970
Accidents cardiaques et neurologiques dûs à la phénylpropanolamine [in French]. La Revue Prescrire 1999; 19: 599
Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343: 1826–32
Charatan F. Phenylpropanolamine in drugs could bear risk for stroke [news]. BMJ 2000; 321: 1037
Phenylpropanolamine: strengthening of patient information. United Kingdom. WHO Drug Information 2001; 14: 226
Phenylpropanolamine and other OTC alpha-adrenergic agonists. Med Letter Drugs Ther 2000; 42: 113
Lee KY, Beilin LJ, Vandongen R. Severe hypertension after ingestion of an appetite suppressant (phenylpropanolamine) with indomethacin [letter]. Lancet 1979; I: 110–1
Bennett WM. Hazards of the appetite suppressant phenylpropanolamine [letter]. Lancet 1979; II: 42–3
Jick H, Aselton P, Hunter JR. Phenylpropanolamine and cerebral haemorrhage [letter]. Lancet 1984; I: 1017
Strom BL, Carson JL. Use of automated databases for pharmacoepidemiology research. Epidemiol Rev 1990; 12: 87–107
Lake RC, Gallant S, Masson E. Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports. Am J Med 1990; 89: 195–208
Taverner D, Bickford L, Draper M. Nasal decongestants for the common cold (Cochrane Review). In: The Cochrane Library, Issue 4, 2000. Oxford: Update Software
Fleming GA. The FDA, regulation and the risk of stroke. N Engl J Med 2000; 343: 1886–7
Acknowledgements
We acknowledge the active participants in the electronic discussion lists e-farmacos and e-drugs. We are also grateful to Dr Dolors Capellà (Fundació ICF, Barcelona, Spain) for her useful comments and suggestions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Figueras, A., Laporte, JR. Regulatory Decisions in a Globalised World. Drug-Safety 25, 689–693 (2002). https://doi.org/10.2165/00002018-200225100-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200225100-00001